WO2023218423 - INDAZOLES AND THEIR USE IN METHODS FOR TREATING 5-HT2 RESPONSIVE CONDITIONS
National phase entry is expected:
Publication Number
WO/2023/218423
Publication Date
16.11.2023
International Application No.
PCT/IB2023/054940
International Filing Date
12.05.2023
Title **
[English]
INDAZOLES AND THEIR USE IN METHODS FOR TREATING 5-HT2 RESPONSIVE CONDITIONS
[French]
INDAZOLES ET LEUR UTILISATION DANS DES MÉTHODES DE TRAITEMENT D'AFFECTIONS SENSIBLES AU 5-HT2
Applicants **
ELEUSIS THERAPEUTICS US, INC.
Inventors
JOHNSON, Graham
Priority Data
63/341,287
12.05.2022
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
USPTO
* |
| * | |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2712 | |
| EPO | Filing, Examination, Granting | 19886 | |
| Japan | Filing, Examination, Granting | 2616 | |
| South Korea | Filing, Examination, Granting | 3125 | |
| USA | Filing, Examination, Granting | 8110 |
Total:
36,449
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The invention features indazole-linked azetidine and indazole-linked methylethanamine compounds as small molecule 5-HT2 receptor ligands, and pharmaceutical compositions thereof, useful for treating 5-HT2 responsive conditions, such as arthritis, diabetes, Alzheimer's, inflammation and depression. Disclosed are synthetic methods for the preparation of such novel indazole compounds and methods of using the compounds and/or compositions of the invention for treating 5-HT2 responsive conditions in a subject in need thereof.[French]
L'invention concerne des composés méthyléthanamine lié à l'indazole et azétidine lié à l'indazole comme ligands du récepteur 5-HT2 à petites molécules, et des compositions pharmaceutiques de ceux-ci utiles pour traiter des affections sensibles au 5-HT2, tels que l'arthrite, le diabète, l'inflammation et la dépression associées à la maladie d'Alzheimer. L'invention concerne également des procédés synthétiques de préparation de tels nouveaux composés indazole et des procédés d'utilisation des composés et/ou compositions de l'invention pour traiter des affections sensibles au 5-HT2 chez un sujet dont l'état le nécessite.